Commodore Capital LP Tricida, Inc. Transaction History

Commodore Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $451,455 - $721,480	-53,050 Reduced 2.62%	1,975,403 $20.7 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $2.08 Million - $3.36 Million	283,883 Added 16.27%	2,028,453 $19.6 Million
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $3.66 Million - $5.29 Million	497,527 Added 39.9%	1,744,570 $14.3 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $5.23 Million - $11.9 Million	1,247,043 New	1,247,043 $11.9 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.